SatraGO-2 Study
...for Graves' Orbitopathy

Thyroid Eye Disease (TED)

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-To-Severe Thyroid Eye Disease

Inclusion Criteria:
• At least 18 years old
• Have no/controlled or mild thyroid problems
• Have active TED that began less than 1 year before the trial
• Or, have had TED for between 1-10 years and chronic inactive TED for at least 6 months

Exclusion Criteria:
• Received certain treatments, including an IL-6 targeted medicine
• History of cancer or certain drug allergies
• Are pregnant or breastfeeding

Principal Investigator:
Raymond Cho, MD

Ohio State Department of Ophthalmology & Visual Sciences • 614-293-5287 • Research@osumc.edu

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.